LSM8

Summary

LSM8 (LSM8 homolog, U6 small nuclear RNA associated, HGNC:20471) is a protein-coding gene on chromosome 7q31.31, encoding U6 snRNA-associated Sm-like protein LSm8 (O95777). Plays a role in pre-mRNA splicing as component of the U4/U6-U5 tri-snRNP complex that is involved in spliceosome assembly, and as component of the precatalytic spliceosome (spliceosome B complex). It is a common-essential gene (DepMap: required in 99.7% of cancer cell lines).

This gene encodes a member of the like-Sm family of proteins. The encoded protein consists of a closed barrel shape, made up of five anti-parallel beta strands and an alpha helix. This protein partners with six paralogs to form a heteroheptameric ring which transiently binds U6 small nuclear RNAs and is involved in the general maturation of RNA in the nucleus.

Source: NCBI Gene 51691 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 7 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.7% of screened cell lines (common-essential)
• MANE Select transcript: NM_016200

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20471
Approved symbol	LSM8
Name	LSM8 homolog, U6 small nuclear RNA associated
Location	7q31.31
Locus type	gene with protein product
Status	Approved
Aliases	YJR022W
Ensembl gene	ENSG00000128534
Ensembl biotype	protein_coding
OMIM	607288
Entrez	51691

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000249299, ENST00000411938, ENST00000422760, ENST00000424702, ENST00000915332, ENST00000915333

RefSeq mRNA: 1 — MANE Select: NM_016200 NM_016200

CCDS: CCDS5775

Canonical transcript exons

ENST00000249299 — 4 exons

Exon	Start	End
ENSE00001018687	118185654	118185694
ENSE00001129736	118184164	118184254
ENSE00001217918	118191912	118204035
ENSE00003785688	118188278	118188405

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 93.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 82.2435 / max 839.3366, expressed in 1827 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
80732	50.3253	1824
80731	31.8865	1822
80733	0.0317	5

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	93.97	gold quality
colonic epithelium	UBERON:0000397	92.01	gold quality
heart right ventricle	UBERON:0002080	91.89	gold quality
ventricular zone	UBERON:0003053	91.43	gold quality
monocyte	CL:0000576	91.23	gold quality
bone marrow	UBERON:0002371	91.23	gold quality
leukocyte	CL:0000738	91.16	gold quality
mononuclear cell	CL:0000842	91.16	gold quality
bone marrow cell	CL:0002092	90.90	gold quality
upper leg skin	UBERON:0004262	90.79	gold quality
granulocyte	CL:0000094	90.74	gold quality
oocyte	CL:0000023	90.41	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.20	gold quality
cartilage tissue	UBERON:0002418	90.15	gold quality
corpus epididymis	UBERON:0004359	90.07	gold quality
embryo	UBERON:0000922	90.02	gold quality
ganglionic eminence	UBERON:0004023	89.87	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	89.55	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.47	gold quality
blood vessel layer	UBERON:0004797	89.46	gold quality
tendon	UBERON:0000043	89.28	gold quality
mucosa of sigmoid colon	UBERON:0004993	89.27	gold quality
bone element	UBERON:0001474	88.89	gold quality
vermiform appendix	UBERON:0001154	88.66	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.52	gold quality
oral cavity	UBERON:0000167	88.49	gold quality
skin of hip	UBERON:0001554	88.34	gold quality
colonic mucosa	UBERON:0000317	88.25	gold quality
adrenal tissue	UBERON:0018303	88.22	gold quality
seminal vesicle	UBERON:0000998	87.82	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.77
E-MTAB-6386	no	291.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

426 targeting LSM8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4668-3P	100.00	68.74	2635

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• LSm8 controls nuclear accumulation of all LSm2-7 proteins and the number of cytoplasmic processing bodies. (PMID:22875987)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	lsm8	ENSDARG00000091656
mus_musculus	Lsm8	ENSMUSG00000044155
rattus_norvegicus	Lsm8	ENSRNOG00000070946
drosophila_melanogaster	CG2021	FBGN0035271
caenorhabditis_elegans		WBGENE00003082

Paralogs (1): LSM1 (ENSG00000175324)

Protein

Protein identifiers

U6 snRNA-associated Sm-like protein LSm8 — O95777 (reviewed: O95777)

All UniProt accessions (5): O95777, A4D0W0, C9JIZ0, C9JNV3, F2Z2Y6

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in pre-mRNA splicing as component of the U4/U6-U5 tri-snRNP complex that is involved in spliceosome assembly, and as component of the precatalytic spliceosome (spliceosome B complex). The heptameric LSM2-8 complex binds specifically to the 3’-terminal U-tract of U6 snRNA.

Subunit / interactions. Component of the precatalytic spliceosome (spliceosome B complex). Component of the U4/U6-U5 tri-snRNP complex, a building block of the precatalytic spliceosome (spliceosome B complex). The U4/U6-U5 tri-snRNP complex is composed of the U4, U6 and U5 snRNAs and at least PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, SNRNP200, TXNL4A, SNRNP40, SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF, SNRPG, DDX23, CD2BP2, PPIH, SNU13, EFTUD2, SART1 and USP39, plus LSM2, LSM3, LSM4, LSM5, LSM6, LSM7 and LSM8. LSM2, LSM3, LSM4, LSM5, LSM6, LSM7 and LSM8 form a heptameric, ring-shaped subcomplex (the LSM2-8 complex) that is part of the U4/U6-U5 tri-snRNP complex and the precatalytic spliceosome.

Subcellular location. Nucleus.

Similarity. Belongs to the snRNP Sm proteins family.

RefSeq proteins (1): NP_057284* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001163	Sm_dom_euk/arc	Domain
IPR010920	LSM_dom_sf	Homologous_superfamily
IPR034103	Lsm8	Domain
IPR044642	PTHR15588	Family
IPR047575	Sm	Domain

Pfam: PF01423

UniProt features (4 total): initiator methionine 1, chain 1, domain 1, modified residue 1

Structure

Experimental structures (PDB)

20 structures.

PDB	Method	Resolution (Å)
8H6L	ELECTRON MICROSCOPY	2.6
8H6K	ELECTRON MICROSCOPY	2.7
6QW6	ELECTRON MICROSCOPY	2.92
8H6E	ELECTRON MICROSCOPY	3.2
8H6J	ELECTRON MICROSCOPY	3.25
6QX9	ELECTRON MICROSCOPY	3.28
6AHD	ELECTRON MICROSCOPY	3.8
8QZS	ELECTRON MICROSCOPY	4.1
8R09	ELECTRON MICROSCOPY	4.3
8R0B	ELECTRON MICROSCOPY	4.4
5O9Z	ELECTRON MICROSCOPY	4.5
8QO9	ELECTRON MICROSCOPY	5.29
6AH0	ELECTRON MICROSCOPY	5.7
8R0A	ELECTRON MICROSCOPY	5.8
8R08	ELECTRON MICROSCOPY	6.1
8RM5	ELECTRON MICROSCOPY	6.9
3JCR	ELECTRON MICROSCOPY	7
7ABG	ELECTRON MICROSCOPY	7.8
9R8V	ELECTRON MICROSCOPY	8.5
8QXD	ELECTRON MICROSCOPY	9.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95777-F1	95.53	0.94

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-72172	mRNA Splicing
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 161 (showing top): TGCGCANK_UNKNOWN, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, GOBP_SPLICEOSOMAL_TRI_SNRNP_COMPLEX_ASSEMBLY, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, GNF2_FBL, GOBP_PROTEIN_RNA_COMPLEX_ORGANIZATION, GOBP_RNA_SPLICING, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, REACTOME_MRNA_SPLICING, DODD_NASOPHARYNGEAL_CARCINOMA_UP, BASAKI_YBX1_TARGETS_DN, SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP, DANG_BOUND_BY_MYC, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS

GO Biological Process (3): mRNA splicing, via spliceosome (GO:0000398), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (4): RNA binding (GO:0003723), mRNA binding (GO:0003729), U6 snRNA binding (GO:0017070), protein binding (GO:0005515)

GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), U6 snRNP (GO:0005688), U4/U6 x U5 tri-snRNP complex (GO:0046540), U2-type precatalytic spliceosome (GO:0071005), precatalytic spliceosome (GO:0071011), Lsm2-8 complex (GO:0120115), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
mRNA Splicing	1
Processing of Capped Intron-Containing Pre-mRNA	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
mRNA metabolic process	1
nucleic acid binding	1
RNA binding	1
snRNA binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
spliceosomal snRNP complex	1
Lsm2-8 complex	1
U5 snRNP	1
U4/U6 snRNP	1
spliceosomal tri-snRNP complex	1
U2-type spliceosomal complex	1
U1 snRNP	1
U2 snRNP	1
U4/U6 x U5 tri-snRNP complex	1
precatalytic spliceosome	1
spliceosomal complex	1
Sm-like protein family complex	1
protein-containing complex	1

Protein interactions and networks

STRING

2216 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LSM8	LSM2	Q9Y333	999
LSM8	LSM3	P62310	993
LSM8	LSM4	Q9Y4Z0	993
LSM8	LSM7	Q9UK45	990
LSM8	LSM6	P62312	986
LSM8	LSM5	Q9Y4Y9	984
LSM8	XRN1	Q8IZH2	922
LSM8	SNRPD2	P43330	871
LSM8	SNRPE	P08578	713
LSM8	SNRPD1	P13641	713
LSM8	SNRPD3	P43331	710
LSM8	USB1	Q9BQ65	690
LSM8	LSM1	O15116	618
LSM8	SART3	Q15020	617
LSM8	EXOSC6	Q5RKV6	593

IntAct

173 interactions, top by confidence:

A	B	Type	Score
LSM3	LSM1	psi-mi:“MI:0914”(association)	0.950
PRPF4	PPIH	psi-mi:“MI:0914”(association)	0.910
LSM2	LSM8	psi-mi:“MI:0915”(physical association)	0.790
LSM3	LSM8	psi-mi:“MI:0915”(physical association)	0.780
SART3	PRPF4	psi-mi:“MI:0914”(association)	0.730
SNRPB	PRMT5	psi-mi:“MI:0914”(association)	0.670
LSM5	LSM1	psi-mi:“MI:0914”(association)	0.640
DCTN1	LSM8	psi-mi:“MI:0915”(physical association)	0.560
	LSM8	psi-mi:“MI:0915”(physical association)	0.560
LSM8		psi-mi:“MI:0915”(physical association)	0.560
PRKN	LSM8	psi-mi:“MI:0915”(physical association)	0.560
LSM8	PMP22	psi-mi:“MI:0915”(physical association)	0.560
UCHL1	LSM8	psi-mi:“MI:0915”(physical association)	0.560
LSM8	SOD1	psi-mi:“MI:0915”(physical association)	0.560
LSM8	SNCA	psi-mi:“MI:0915”(physical association)	0.560
LSM8	HTT	psi-mi:“MI:0915”(physical association)	0.560
LSM8	TARDBP	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (152): LSM8 (Two-hybrid), PGD (Two-hybrid), LSM8 (Two-hybrid), IGHMBP2 (Two-hybrid), SNRPD1 (Two-hybrid), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS), GTF2I (Two-hybrid), LSM8 (Affinity Capture-MS), LSM8 (Affinity Capture-MS)

ESM2 similar proteins: A1CE19, A1DM27, A4RQ29, A5DRQ6, A6R363, A6S5C9, A7F5M4, A7UXE4, A8NHT8, B0DWN3, C5A1H1, O22823, O26745, O43080, O59734, O74966, O82221, O95777, P0CR24, P0CR25, P24715, P34659, P38203, P54999, P57743, P62312, P62313, Q0UWI9, Q0W8R9, Q12U30, Q1DRN0, Q24297, Q2HAN0, Q3ZCE0, Q465S1, Q4PG71, Q4WNI0, Q54RX0, Q54XP2, Q5RCP3

Diamond homologs: A2BIG9, A4IGZ4, O43080, O95777, P91918, Q10163, Q3ZCE0, Q55A45, Q5RCP3, Q6GQ67, Q6NU60, Q6ZWM4, Q8IPZ7, Q9BRA0, Q9D2U5, O15116, O74483, O74966, O82221, P24715, P47017, P87173, Q1ZXD5, Q54W83, Q5E9Z8, Q8LFL8, Q8VC85, Q8VYI0, Q945P8, Q9VXE0, O74499, P14678, P17136, P27048, P40018, P47093, P53905, P62308, P62309, P63162

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
LSM8	“form complex”	“U4/U6.U5 snRNP complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 94 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
mRNA decay by 5’ to 3’ exoribonuclease	8	85.8×	8e-13
Metabolism of non-coding RNA	6	53.6×	3e-08
mRNA Splicing - Minor Pathway	7	22.1×	8e-07
mRNA Splicing	14	21.6×	2e-13
snRNP Assembly	7	20.9×	1e-06
SARS-CoV-2 modulates host translation machinery	6	18.9×	1e-05
mRNA Splicing - Major Pathway	22	16.9×	3e-19
Processing of Capped Intron-Containing Pre-mRNA	14	16.2×	6e-12

GO biological processes:

GO term	Partners	Fold	FDR
spliceosomal snRNP assembly	10	68.4×	4e-14
RNA splicing, via transesterification reactions	5	36.7×	2e-05
U2-type prespliceosome assembly	5	36.7×	2e-05
spliceosomal complex assembly	5	35.4×	2e-05
mRNA splicing, via spliceosome	22	23.7×	9e-22
RNA splicing	16	16.6×	3e-13
protein deubiquitination	5	10.4×	6e-03
mRNA processing	8	7.4×	8e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

7 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

961 predictions. Top by Δscore:

Variant	Effect	Δscore
7:118188404:GT:G	donor_gain	1.0000
7:118188406:G:GG	donor_gain	1.0000
7:118191910:A:AG	acceptor_gain	1.0000
7:118191911:G:GA	acceptor_gain	1.0000
7:118191911:GT:G	acceptor_gain	1.0000
7:118191911:GTGCA:G	acceptor_gain	1.0000
7:118184277:GGGC:G	donor_gain	0.9900
7:118184278:G:GT	donor_gain	0.9900
7:118184278:GGC:G	donor_gain	0.9900
7:118184279:GC:G	donor_gain	0.9900
7:118184279:GCG:G	donor_gain	0.9900
7:118184281:G:GG	donor_gain	0.9900
7:118184323:G:T	donor_gain	0.9900
7:118185031:G:GG	donor_gain	0.9900
7:118185065:GCC:G	donor_gain	0.9900
7:118185645:A:AG	acceptor_gain	0.9900
7:118185646:G:GG	acceptor_gain	0.9900
7:118188276:A:AG	acceptor_gain	0.9900
7:118188276:A:T	acceptor_loss	0.9900
7:118188276:AG:A	acceptor_gain	0.9900
7:118188276:AGG:A	acceptor_gain	0.9900
7:118188277:G:GG	acceptor_gain	0.9900
7:118188277:GG:G	acceptor_gain	0.9900
7:118188277:GGG:G	acceptor_gain	0.9900
7:118188277:GGGA:G	acceptor_gain	0.9900
7:118188356:G:GT	donor_gain	0.9900
7:118188370:G:GA	donor_gain	0.9900
7:118188397:TGACA:T	donor_gain	0.9900
7:118188399:ACAAC:A	donor_gain	0.9900
7:118188402:ACGT:A	donor_gain	0.9900

AlphaMissense

615 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:118188279:G:A	G25E	1.000
7:118185660:T:A	V13D	0.999
7:118188278:G:A	G25R	0.999
7:118188278:G:C	G25R	0.999
7:118188290:G:C	G29R	0.999
7:118188310:T:A	N35K	0.999
7:118188310:T:G	N35K	0.999
7:118188326:A:C	S41R	0.999
7:118188328:C:A	S41R	0.999
7:118188328:C:G	S41R	0.999
7:118188378:G:A	G58E	0.999
7:118188393:G:T	R63I	0.999
7:118188395:G:C	G64R	0.999
7:118188396:G:A	G64D	0.999
7:118188396:G:T	G64V	0.999
7:118185666:T:A	V15D	0.998
7:118185680:G:T	G20W	0.998
7:118185681:G:A	G20E	0.998
7:118185681:G:T	G20V	0.998
7:118188279:G:T	G25V	0.998
7:118188285:T:C	L27P	0.998
7:118188297:A:T	D31V	0.998
7:118188298:C:A	D31E	0.998
7:118188298:C:G	D31E	0.998
7:118188315:T:A	I37N	0.998
7:118188318:T:C	L38S	0.998
7:118188336:G:C	R44P	0.998
7:118188377:G:A	G58R	0.998
7:118188377:G:C	G58R	0.998
7:118188378:G:T	G58V	0.998

dbSNP variants (sampled 300 via entrez): RS1000164092 (7:118190534 T>C), RS1000217694 (7:118190259 G>A), RS1000218936 (7:118193904 A>C), RS1000300075 (7:118195465 G>A,T), RS1000355276 (7:118195742 T>C), RS1000423237 (7:118203299 C>T), RS1000440978 (7:118196496 C>T), RS1000459867 (7:118184535 A>C,T), RS1000492866 (7:118189281 A>G), RS1000543871 (7:118189156 A>G), RS1000558211 (7:118189496 C>G,T), RS1000671468 (7:118184152 T>A,G), RS1000787024 (7:118183988 G>A), RS1000877829 (7:118201288 T>C,G), RS1000895155 (7:118196170 T>C,G)

Disease associations

OMIM: gene MIM:607288 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST002408_2	Response to methotrexate in juvenile idiopathic arthritis	5.000000e-07
GCST002408_3	Response to methotrexate in juvenile idiopathic arthritis	6.000000e-06
GCST005580_180	Intraocular pressure	2.000000e-08
GCST006065_3	Glaucoma (primary open-angle)	1.000000e-08
GCST006436_4	Triglyceride levels	2.000000e-08
GCST007624_1	Positive urgency	9.000000e-07
GCST007831_1	Anti-thyroglobulin (TgAb) levels in Hashimoto’s thyroiditis	2.000000e-07
GCST007851_2	Anti-thyroid peroxidase (TPOAb) and anti-thyroglobulin (TgAb) levels in Hashimoto’s thyroiditis	2.000000e-06
GCST008368_10	Plasma anti-thyroid peroxidase levels	4.000000e-06
GCST011703_84	Smoking initiation	5.000000e-16
GCST011704_7	Smoking status (current vs never)	7.000000e-09
GCST90011766_14	Glaucoma (primary open-angle)	9.000000e-09
GCST90011770_13	Glaucoma (primary open-angle)	8.000000e-17

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004695	intraocular pressure measurement
EFO:0004530	triglyceride measurement
EFO:0006946	behavioural disinhibition measurement
EFO:0005670	smoking initiation
EFO:0006527	smoking status measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465283 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	5
bisphenol A	increases expression, increases methylation	2
trichostatin A	affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
methylmercuric chloride	decreases expression	1
sodium arsenate	increases expression	1
arsenite	affects binding, increases reaction	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Ribonucleotides	affects binding	1
Theophylline	affects cotreatment, decreases expression	1
Tretinoin	decreases expression	1
Cyclosporine	increases expression	1
Sodium Selenite	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5338445	Binding	Binding affinity to Lsm8 (unknown origin) at 200 uM preincubated for 2 hrs followed by pronase addition and measured after 30 mins by coomassie blue staining based SDS-PAGE gel analysis	Structurally Diverse Alkaloids with Anti-Renal-Fibrosis Activity from the Centipede Scolopendra subspinipes mutilans. — J Nat Prod

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.